



CIN NO.: L24230WB1982PLC034492

Date: 29th October, 2021

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Outcome of Board Meeting held on 29th October, 2021

This is to inform you that, Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Director at its meeting was held at its Registered Office on Friday, 29th October, 2021 (**commenced at 11:00 AM and concluded at 11.40 A.M.**) have inter-alia considered, approved and adopted the following agenda:

1. Standalone Unaudited Financial Results of the Company for the 02nd quarter ended 30th September, 2021.
2. Limited Review Report issued by the Statutory Auditors on Standalone Unaudited Financial Results for 02nd quarter ended 30th September, 2021.
3. The undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is enclosed herewith.


This information is also available on Company's website: www.adinathbio.com and on the stock exchange website: www.cse-india.com.

The Company would be publishing Extract of Unaudited Financial Result for the 02nd Quarter ended 30-09-2021, in accordance with Regulation 47(1) (b) of the Listing Regulation.

Request you to kindly take the above on record.

Thanking you,
Yours faithfully,
For Adinath Bio-Labs Limited


Kishan Singh
(Whole-Time Director)
(DIN: 07526266)



Encl.: As above.


Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2021							
PART I						(Amount in Rs.)	
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		(30/09/2021)	(30/06/2021)	(30/09/2020)	(30/09/2021)	(30/09/2020)	(31/03/2021)
1	Income from operations						
	(a) Net Sales / income from operations	-	-	-	-	-	-
	(b) Other Income	63,770	63,077	63,770	1,26,847	1,26,847	2,53,000
	Total income from operations (net)	63,770	63,077	63,770	1,26,847	1,26,847	2,53,000
2	Expenses						
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-	-
	(b) Employee benefits expense	1,35,620	1,35,610	1,36,235	2,71,230	2,72,289	5,45,113
	(c) Finance Cost	-	-	-	-	-	-
	(d) Depreciation and amortisation expense	348	348	6,161	696	12,322	24,644
	(e) Other expenses	1,20,645	2,52,637	88,044	3,73,282	3,46,523	5,65,094
	Total expenses	2,56,613	3,88,595	2,30,440	6,45,208	6,31,134	11,34,851
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(1,92,843)	(3,25,518)	(1,66,670)	(5,18,361)	(5,04,287)	(8,81,851)
4	Exceptional & Extraordinary Items	25,46,841	48,91,297	48,70,000	74,38,138	1,08,70,000	1,52,70,000
5	Profit / (Loss) before Tax (3 ± 4)	(27,39,684)	(52,16,815)	(50,36,670)	(79,56,499)	(1,13,74,287)	(1,61,51,851)
6	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
	Earlier Years	-	-	-	-	-	-
	Total Tax Expenses
7	Net Profit/(Loss) after tax(5 ± 6)	(27,39,684)	(52,16,815)	(50,36,670)	(79,56,499)	(1,13,74,287)	(1,61,51,851)
8	Other Comprehensive Income / (Loss)
9	Total Comprehensive Income / (Loss) (7 ± 8)	(27,39,684)	(52,16,815)	(50,36,670)	(79,56,499)	(1,13,74,287)	(1,61,51,851)
10	Paid-up equity share capital	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560
	(Face Value in Re.)	1	1	1	1	1	1
11	Earnings Per Share (Not annualised except for year ended)						
	Basic & Diluted	(0.01)	(0.02)	(0.02)	(0.04)	(0.05)	(0.07)



Statement of Assets and Liabilities as on 30th September, 2021

(Amount in Rs.)

Sl. No.	Particulars	As at 30th September, 2021	As at 31st March, 2021
		Unaudited	Audited
I	ASSETS		
A	Non-current assets		
	a) Property, plant and equipment	1,45,426	1,46,122
	b) Financial assets		
	i) Investments	2,87,500	2,87,500
	ii) Other Non current financial assets	76,37,254	1,54,76,015
	Total Non-current assets	80,70,180	1,59,09,637
B	Current assets		
	a) Financial assets		
	i) Trade Receivables	-	-
	ii) Cash and cash equivalents	95,863	3,868
	iii) Loans	25,30,000	25,30,000
	iv) Other current financial assets	5,65,806	9,11,606
	Total Current assets	31,91,669	34,45,474
	TOTAL ASSETS	1,12,61,849	1,93,55,111
II	EQUITY AND LIABILITIES		
A	EQUITY		
	a) Equity Share capital	22,07,42,560	22,07,42,560
	b) Other Equity	(21,80,58,361)	(21,01,01,862)
	Total equity	26,84,199	1,06,40,698
B	LIABILITIES		
I	Non-current liabilities		
	(a) Deferred tax liabilities (net)	-	-
	Total Non-current liabilities	-	-
II	Current liabilities		
	a) Financial liabilities	-	-
	b) Other current liabilities	1,30,335	2,67,098
	c) Current tax liabilities	84,47,315	84,47,315
	Total Current liabilities	85,77,650	87,14,413
	TOTAL EQUITY AND LIABILITIES	1,12,61,849	1,93,55,111


 By order of the Board
 For Adinath Bio-Labs Limited

 Kishan Singh
 Whole Time Director
 DIN :07526266

 Date: 29th October, 2021
 Place: Kolkata

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2021		
(Amount in Rs.)		
Particulars	For the Half Year Ended 30th September, 2021	For the Year Ended 31st March, 2021
(A) Cash Flow From Operating Activities		
Net Profit before Tax & Exceptional items	(5,18,361)	(8,81,851)
Adjustments for :-		
Provision for diminution in value of investments	-	-
Provision for doubtful debts	-	-
Fixed Assets Written off	-	-
Other Income	(1,26,847)	(2,53,000)
Depreciation and Amortisation on tangible assets	696	24,644
Operating Profit Before Working Capital Changes	(6,44,512)	(11,10,207)
Adjustments for :-		
Working/ Operating Capital Changes		
(Increase)/ Decrease in Other Receivables	7,46,423	4,76,073
Increase/ (Decrease) in Other Current Liabilities	(1,36,763)	1,47,392
Cash Generated From Operations	(34,852)	(4,86,742)
Payment of Taxes	-	-
Net Cash Flow (Used in)/ Generated From Operating Activities (A)	(34,852)	(4,86,742)
(B) Cash Flow From Investing Activities		
Receipt/ (Repayment) of loan and advances	-	-
Interest (Net)	1,26,847	2,53,000
Net Cash Flow (Used in)/ Generated From Investing Activities (B)	1,26,847	2,53,000
(C) Cash Flow From Financing Activities		
Net Cash Flow (Used in)/ Generated From Financing Activities (C)	-	-
Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C)	91,995	(2,33,742)
Cash & Cash Equivalents as at the beginning of the year	3,868	2,37,610
Cash & Cash Equivalents as at the end of the year	95,863	3,868


Notes:

- The above Unaudited Financial results have been reviewed by the Audit committee at their meeting held on 29th October, 2021 and adopted by the Board of Directors at their meeting held on 29th October, 2021.
- The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.



- 4 The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2021 and issued an unqualified report in this behalf.
- 5 Provisions for income tax and deferred tax will be made at the end of the year except for those which pertains to earlier years on account of any specific order received by the company.
- 6 The accumulated losses have eroded net worth to the extent of 50% of the capital of the Company.
- 7 An amount of Rs.25.47 lacs have been provided and charged to profit and loss account under exceptional items on account of provision for doubtful receivables for the quarter ended 30th September, 2021.
- 8 The full impact of COVID-19 still remains uncertain and could be different from our estimates when we prepared these financial results. The Company will continue to closely monitor any material changes to future economic conditions.
- 9 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

By order of the Board
For Adinath Bio-Labs Limited



Kishan Singh
Whole Time Director
DIN :07526266

Date: 29th October, 2021

Place: Kolkata



CIN NO.: L24230WB1982PLC034492

Date: 29th October, 2021

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Non- applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc..-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.


In view of the aforesaid, I, the undersigned, Mr. Kishan Singh, Whole Time Director of Adinath Biolabs Limited hereby certify that Compliances of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company, as the company has not issued any share by way of public issue, right issue, preferential issue etc. during the quarter ended on 30th September, 2021.

You are requested to take the above information in your records.

Thanking you,
Yours faithfully,

For Adinath Bio-Labs Limited

Kishan Singh
(Whole-Time Director)
DIN: 007526266



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Adinath Bio-Labs Limited


We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the quarter and half year ended on 30th September, 2021 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA & Co.
Chartered Accountants
FRN: 003822C


Kamal Piyush
Partner

Membership No.: 083399

Place: Delhi

Date: 29/10/2021

UDIN: 21083399AAAEL6667